Search the Newsreel

CytoMed Therapeutics (GDTC) chair discloses 24.3% share stake

CytoMed Therapeutics Ltd's Chairman and Director, Choo Chee Kong, has filed an amended ownership report revealing he beneficially owns 2,899,746 ordinary shares, representing 24.30% of the company's outstanding shares. His holdings include shares through Glorious Finance Limited, EP Capital Inc., and directly. Between July …

Lifecore Biomedical (LFCR) Proxy filing Summary

Lifecore Biomedical (LFCR) has released a summary of its proxy filing for the upcoming 2024 annual meeting, to be held virtually on November 7, 2024. Shareholders will vote on director elections, auditor ratification, and executive compensation, with the board recommending approval for all proposals. …

Lifecore Biomedical (LFCR) Q1 2026 earnings summary

Lifecore Biomedical's Q1 2026 summary highlights significant revenue growth in Q3 2025, reaching $31.1 million, driven by increased demand, new business wins, and strong manufacturing growth. The company strengthened its leadership, implemented operational efficiencies, and advanced its pipeline with 11 programs targeting launches between …

Advanced Biomed Inc. (NASDAQ:ADVB) jumps as $25 million equity facility concludes

Advanced Biomed Inc. (NASDAQ:ADVB) saw its shares jump 74.6% after the company terminated a $25 million equity facility, which was 2.1 times its preliminary market value. The market reacted positively to the elimination of potential future share issuance, despite losing an optional cash source. …

12 Health Care Stocks Moving In Wednesday's Intraday Session

This article lists 12 healthcare stocks experiencing significant price movements during Wednesday's intraday trading session. It highlights both gainers, such as Advanced Biomed (up 108.6%) and Lakewood-Amedex (up 82.79%), and losers, including China Pharma Holding (down 77.3%) and Zhengye Biotechnology (down 49.3%). The piece …

Ping An Biomedical (Nasdaq: PASW) targets RMB 500m sales via health partnership

Ping An Biomedical (Nasdaq: PASW) announced a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services, targeting cumulative sales of RMB 500 million within three years in the health and wellness market. Yuan Sheng Mei Yan will act as a channel development service …

ADVB Stock Spikes On Volatility As Traders Lock In

Advanced Biomed Inc. (ADVB) stock surged by 29.1% due to promising clinical trial news, demonstrating significant volatility with multi-day runs and aggressive intraday swings. Despite a strong balance sheet with high liquidity and low debt, the company faces substantial cash burn and quarterly losses …

A health-services partner will help expand Ping An Biomedical product channels

Ping An Biomedical (NASDAQ: PASW) has signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services, aiming for RMB 500 million in cumulative sales over three years. Yuan Sheng Mei Yan will act as a channel development service provider, leveraging its health …

Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years

Ping An Biomedical Co., Ltd. (Nasdaq: PASW) and Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd. have signed a strategic cooperation agreement aimed at achieving RMB 500 million in cumulative sales within three years in the health and wellness services market. Under the …

EQS-Adhoc: Ad-hoc: Marinomed Biotech AG beantragt gerichtliches Sanierungsverfahren ohne Eigenverwaltung - boerse.de

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Advanced Biomed Ends Equity Purchase Agreement Facility

Advanced Biomed Inc. has terminated its equity purchase agreement facility with Helena Global Investment Opportunities I Ltd., effective July 21, 2026. This agreement, established on June 6, 2025, allowed Advanced Biomed to sell up to $25 million of common stock, but the company only …

Ping An Biomedical Bolsters Hong Kong IP Portfolio with USD 2.5 Million Trademark Acquisition

Ping An Biomedical, through its subsidiary Meridian Industries Limited, acquired trademarks for $2.5 million, with the transaction completing on July 10, 2026. This acquisition, disclosed in a Form 6-K, aims to strengthen the company's intellectual property portfolio and brand positioning in Hong Kong. The …

Market Movers | Winners: ADVB, LVLU, ONCO | Losers: QMLS, DARE, PLAG

On a quiet day for the major indices, individual stocks experienced significant swings, with Advanced Biomed (ADVB) gaining 76.9% and QumulusAI (QMLS) falling 33.5%. The article highlights the top daily winners and losers, noting that such large moves often occur in smaller companies and …

Advanced Biomed Stock Is Surging: Here's Why It Is Trending

Advanced Biomed Inc. (NASDAQ: ADVB) shares surged significantly after the company withdrew its Form S-1 registration statement, eliminating a planned securities offering. This move is seen favorably by investors as it removes the prospect of shareholder dilution. The stock climbed 76.94% on Monday and …

Advanced Biomed Inc. SEC Filing (Jul 20, 2026)

Advanced Biomed Inc. has filed a request with the SEC to withdraw its Registration Statement on Form S-1, which was originally filed on July 23, 2025. The company decided not to proceed with the offering registered under the statement at this time, and no …

Advanced Biomed Jumps as Traders Focus on Reduced Dilution Risk and AI Transition

Advanced Biomed's stock (ADVB) jumped 58.7% due to the termination of a $25 million equity purchase agreement, which eased dilution concerns. The company's strategic pivot from life sciences to artificial intelligence also contributed to the rally, attracting speculative momentum for the small-cap stock. Additionally, …

Ping An Biomedical (PASW) enters $2.5M IP sale and purchase deed

Ping An Biomedical Co., Ltd. (PASW), through its subsidiary Meridian Industries Limited, has completed a $2.5 million sale and purchase deed with Multi Ridge (Asia) Limited for certain trademark and intellectual property rights in Hong Kong. The completion occurred on July 10, 2026, with …

Morning Market Movers: BIYA, GVH, ADVB, SDOT See Big Swings

This article highlights significant premarket trading activity for several stocks on Monday, July 20, 2026, noting early price movements as potential trading opportunities. It details top premarket gainers including Baiya International Group Inc. (BIYA) and Advanced Biomed Inc. (ADVB), which saw increases of 75% …

ADVB Stock Surges As Traders Hunt Biotech Momentum

Advanced Biomed Inc. (ADVB) stock surged over 51% following positive biotech news, attracting momentum traders. Despite significant losses, ADVB's strong balance sheet with high working capital and low debt provides operational runway. The stock's price action shows a clear short-term uptrend, with intraday volatility …

Advanced Biomed Shares Surge on Termination of Stock Purchase Agreement

Advanced Biomed (OTC: ADBO) shares surged significantly after the company announced the termination of its common stock purchase agreement with Oasis Capital, LLC. The agreement, originally announced in October 2012, was terminated by mutual consent of both parties. The termination is expected to provide …

Advanced Biomed Delivers Notice To Terminate Purchase Agreement With With Helena Global Investment Opportunities I Ltd On July 14 - SEC Filing

Advanced Biomed (ADVB) has delivered a notice to terminate its purchase agreement with Helena Global Investment Opportunities I Ltd. This termination notice was issued on July 14, as reported in an SEC filing.

Trending Stocks Today | Advanced Biomed Surges 41.46% Post-Market

The article reports that Advanced Biomed (OTC: AOBID) experienced a significant post-market surge of 41.46%. This increase followed the announcement of the acquisition of a 55% stake in the company by a non-U.S. based investment group. The deal is expected to close within twenty …

Advanced Biomed Terminates $25M Equity Purchase Pact With Helena Global Investment Opportunities I

Advanced Biomed (ADVB) terminated its $25 million equity purchase agreement with Helena Global Investment Opportunities I, effective July 21, 2026. This decision removes a potential funding source as the company explores alternative financing options, with no outstanding advance notices or expected penalties. The termination …

12 Health Care Stocks Moving In Friday's After-Market Session

This article lists 12 healthcare stocks that experienced significant movement during Friday's after-market trading session. It details the percentage change and current value for stocks that either gained or declined, including companies like iTonic Holdings, Advanced Biomed, Brookdale Senior Living, Valion Bio, and ALPS …

Advanced Biomed (ADVB) to terminate $25M equity purchase deal with Helena investor

Advanced Biomed Inc. (ADVB) is terminating its $25 million equity purchase agreement with Helena Global Investment Opportunities I Ltd., effective July 21, 2026. The agreement, signed in June 2025, allowed ADVB to sell common stock at its discretion, but the company states no shares …

Short Interest in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Grows By 79.5%

What Triggered Lifecore Biomedical's Recent Stock Plunge

Lifecore Biomedical (LFCR) shares plunged over 33% after its Q4 2025 earnings report, primarily due to delayed volume expectations from key customers and a cautious outlook on new GLP-1 agreements, despite otherwise solid results. The company, a specialized CDMO in aseptic fill-finish and hyaluronic …

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced an inducement grant of 3,500 restricted stock units (RSUs) to a new employee. This RSU award, granted on July 13, 2026, was a material inducement for a newly hired employee to join the company and vests on the …

CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector

CytoMed Therapeutics Ltd, a clinical-stage biotech company spinning off from ASTAR, is developing affordable cancer therapies using allogeneic Gamma Delta T Cells. The company's strategy involves leveraging lower costs in Southeast Asia, partnering with hospitals, and focusing on markets like China and India, while …

H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for CervoMed (NASDAQ: CRVO), indicating a significant potential upside from its current stock price. Despite a recent stock decline, analyst consensus remains strong. The company recently presented new analyses on its investigational …

CRVO Reiterated by HC Wainwright & Co. -- Rating Maintained at B

HC Wainwright & Co. has reiterated a Buy rating for CervoMed (CRVO) with an unchanged price target of $25.00, expressing confidence in the stock's potential. Despite a low GF Score™ of 35/100, which suggests challenges in profitability and growth, the company shows strong financial …

New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years

CervoMed ประกาศข้อมูลใหม่จากการทดลองทางคลินิก ข้อมูลตัวบ่งชี้ทางชีวภาพในพลาสมา และข้อมูลภาพถ่ายทางการแพทย์ ณ งานประชุม AAIC 2026 สำหรับยา Neflamapimod ในการรักษาโรคสมองเสื่อมจากภาวะ Lewy Bodies (DLB)

CervoMed announced new clinical trial data for its drug Neflamapimod at AAIC 2026. The data includes plasma biomarker information and medical imaging data. This information concerns the treatment of Dementia with Lewy Bodies (DLB) with Neflamapimod.

LFCR Q1 2026 Earnings: EPS Misses Estimates, Stock Declines - Financial Summary

Generate Biomedicines Inc. Q1 2026 Earnings: Pre-revenue Biotech Reports Wider-than-Expected Loss, Stock Slightly Down - Core Business Growth